Current and future developments in screening for ovarian cancer (Q39902791)

15 September 2017

title

Current and future developments in screening for ovarian cancer (English)

1 reference

15 September 2017

1 reference

Nicole Urban

1 reference

15 September 2017

Charles Drescher

series ordinal

1 reference

15 September 2017

publication date

1 September 2006

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

page(s)

733-742

1 reference

Tamoxifen and breast density in women at increased risk of breast cancer

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Postmenopausal hormone therapy and change in mammographic density

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Aromatase inhibitors--a triumph of translational oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Association of regular aspirin use and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

COX inhibitors and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Serum lipids, lipid-lowering drugs, and the risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Aromatase inhibitors for breast cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

Lipid-Lowering Drug Use and Breast Cancer in Older Women: A Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.2.5.733

21 January 2018

Identifiers

DOI

10.2217/17455057.2.5.733

1 reference

15 September 2017

1 reference